These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 8873615

  • 1. Analysis of the structure and function of the von Willebrand factor A1 domain using targeted deletions and alanine-scanning mutagenesis.
    Kroner PA, Frey AB.
    Biochemistry; 1996 Oct 15; 35(41):13460-8. PubMed ID: 8873615
    [Abstract] [Full Text] [Related]

  • 2. Identification of a novel 14-3-3zeta binding site within the cytoplasmic domain of platelet glycoprotein Ibalpha that plays a key role in regulating the von Willebrand factor binding function of glycoprotein Ib-IX.
    Yuan Y, Zhang W, Yan R, Liao Y, Zhao L, Ruan C, Du X, Dai K.
    Circ Res; 2009 Dec 04; 105(12):1177-85. PubMed ID: 19875727
    [Abstract] [Full Text] [Related]

  • 3. Purified A2 domain of von Willebrand factor binds to the active conformation of von Willebrand factor and blocks the interaction with platelet glycoprotein Ibalpha.
    Martin C, Morales LD, Cruz MA.
    J Thromb Haemost; 2007 Jul 04; 5(7):1363-70. PubMed ID: 17389010
    [Abstract] [Full Text] [Related]

  • 4. Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. Charged-to-alanine scanning mutagenesis of the A1 domain of human von Willebrand factor.
    Matsushita T, Sadler JE.
    J Biol Chem; 1995 Jun 02; 270(22):13406-14. PubMed ID: 7539426
    [Abstract] [Full Text] [Related]

  • 5. Impact of O-linked glycosylation of the VWF-A1-domain flanking regions on platelet interaction.
    Schulte am Esch J, Robson SC, Knoefel WT, Eisenberger CF, Peiper M, Rogiers X.
    Br J Haematol; 2005 Jan 02; 128(1):82-90. PubMed ID: 15606553
    [Abstract] [Full Text] [Related]

  • 6. Type 2M vWD resulting from a lysine deletion within a four lysine residue repeat in the A1 loop of von Willebrand factor.
    Hilbert L, Jenkins PV, Gaucher C, Meriane E, Collins PW, Pasi KJ, Mazurier C.
    Thromb Haemost; 2000 Aug 02; 84(2):188-94. PubMed ID: 10959688
    [Abstract] [Full Text] [Related]

  • 7. Molecular genetics of von Willebrand disease.
    Mazurier C, Ribba AS, Gaucher C, Meyer D.
    Ann Genet; 1998 Aug 02; 41(1):34-43. PubMed ID: 9599650
    [Abstract] [Full Text] [Related]

  • 8. von Willebrand factor without the A2 domain is resistant to proteolysis.
    Lankhof H, Damas C, Schiphorst ME, Ijsseldijk MJ, Bracke M, Furlan M, Tsai HM, de Groot PG, Sixma JJ, Vink T.
    Thromb Haemost; 1997 May 02; 77(5):1008-13. PubMed ID: 9184419
    [Abstract] [Full Text] [Related]

  • 9. Localization of von willebrand factor-binding sites for platelet glycoprotein Ib and botrocetin by charged-to-alanine scanning mutagenesis.
    Matsushita T, Meyer D, Sadler JE.
    J Biol Chem; 2000 Apr 14; 275(15):11044-9. PubMed ID: 10753907
    [Abstract] [Full Text] [Related]

  • 10. A new mutation, S1285F, within the A1 loop of von Willebrand factor induces a conformational change in A1 loop with abnormal binding to platelet GPIb and botrocetin causing type 2M von Willebrand disease.
    Stepanian A, Ribba AS, Lavergne JM, Fressinaud E, Juhan-Vague I, Mazurier C, Girma JP, Meyer D.
    Br J Haematol; 2003 Feb 14; 120(4):643-51. PubMed ID: 12588351
    [Abstract] [Full Text] [Related]

  • 11. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
    Hillery CA, Mancuso DJ, Evan Sadler J, Ponder JW, Jozwiak MA, Christopherson PA, Cox Gill J, Paul Scott J, Montgomery RR.
    Blood; 1998 Mar 01; 91(5):1572-81. PubMed ID: 9473222
    [Abstract] [Full Text] [Related]

  • 12. A template-assembled synthetic protein surface mimetic of the von Willebrand factor A1 domain inhibits botrocetin-induced platelet aggregation.
    Hauert J, Fernandez-Carneado J, Michielin O, Mathieu S, Grell D, Schapira M, Spertini O, Mutter M, Tuchscherer G, Kovacsovics T.
    Chembiochem; 2004 Jun 07; 5(6):856-64. PubMed ID: 15174170
    [Abstract] [Full Text] [Related]

  • 13. Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen.
    Ribba AS, Loisel I, Lavergne JM, Juhan-Vague I, Obert B, Cherel G, Meyer D, Girma JP.
    Thromb Haemost; 2001 Sep 07; 86(3):848-54. PubMed ID: 11583318
    [Abstract] [Full Text] [Related]

  • 14. Ristocetin and botrocetin involve two distinct domains of von Willebrand factor for binding to platelet membrane glycoprotein Ib.
    Girma JP, Takahashi Y, Yoshioka A, Diaz J, Meyer D.
    Thromb Haemost; 1990 Oct 22; 64(2):326-32. PubMed ID: 1702906
    [Abstract] [Full Text] [Related]

  • 15. Defect of heparin binding in plasma and recombinant von Willebrand factor with type 2 von Willebrand disease mutations.
    Rastegar-Lari G, Ajzenberg N, Ribba AS, Vereycken-Holler V, Legendre P, Villoutreix B, Meyer D, Baruch D.
    Thromb Haemost; 2001 Dec 22; 86(6):1459-65. PubMed ID: 11776314
    [Abstract] [Full Text] [Related]

  • 16. Structure-function relationship of the A1 domain of von Willebrand factor.
    Girma JP, Ribba AS, Meyer D.
    Thromb Haemost; 1995 Jul 22; 74(1):156-60. PubMed ID: 8578449
    [Abstract] [Full Text] [Related]

  • 17. Structure and function of the von Willebrand factor A1 domain: analysis with monoclonal antibodies reveals distinct binding sites involved in recognition of the platelet membrane glycoprotein Ib-IX-V complex and ristocetin-dependent activation.
    De Luca M, Facey DA, Favaloro EJ, Hertzberg MS, Whisstock JC, McNally T, Andrews RK, Berndt MC.
    Blood; 2000 Jan 01; 95(1):164-72. PubMed ID: 10607699
    [Abstract] [Full Text] [Related]

  • 18. Platelet-vessel wall interactions in thrombosis and restenosis role of von Willebrand factor.
    Hoylaerts MF.
    Verh K Acad Geneeskd Belg; 1997 Jan 01; 59(3):161-83. PubMed ID: 9490916
    [Abstract] [Full Text] [Related]

  • 19. The interaction of von Willebrand factor-A1 domain with collagen: mutation G1324S (type 2M von Willebrand disease) impairs the conformational change in A1 domain induced by collagen.
    Morales LD, Martin C, Cruz MA.
    J Thromb Haemost; 2006 Feb 01; 4(2):417-25. PubMed ID: 16420575
    [Abstract] [Full Text] [Related]

  • 20. A3 domain is essential for interaction of von Willebrand factor with collagen type III.
    Lankhof H, van Hoeij M, Schiphorst ME, Bracke M, Wu YP, Ijsseldijk MJ, Vink T, de Groot PG, Sixma JJ.
    Thromb Haemost; 1996 Jun 01; 75(6):950-8. PubMed ID: 8822592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.